about
Genome-wide association with select biomarker traits in the Framingham Heart StudyCollaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study.Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study.Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study.Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease.Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study.Multiple biomarkers for the prediction of first major cardiovascular events and death.Contemporary trends in dyslipidemia in the Framingham Heart Study.Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart StudyAssociation of subcutaneous and visceral adiposity with albuminuria: the Framingham Heart Study.Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies.Changes in erythrocyte membrane trans and marine fatty acids between 1999 and 2006 in older Americans.Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study.Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study.Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart StudyUsefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort)Long-term C-reactive protein variability and prediction of metabolic risk.Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study)Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial.Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.Multiple biomarkers and the risk of incident hypertension.Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT).LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial.The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial.Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study.Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study.
P50
Q21261433-7294314B-B63F-4C7A-94EC-7760DDA585A4Q31100823-D9140CBD-3C2A-4624-A1F1-C05574764C24Q33556561-1B7A5AFA-F5F5-435A-924A-4C1A5064A137Q33639433-371B7B67-A604-461C-9A10-80D256FA9F6DQ33944562-353A04D1-B471-4384-936F-36EA5DF18168Q34032071-EB3A5210-3F76-4FD1-963B-78DDA6B17A57Q34287868-99A6D3F2-9DAD-49D3-BEC3-D05B2C1D3603Q34551435-851C4DDD-B0DF-4FD9-9AA8-F7BE38B646E5Q34593507-CE469A90-711C-4200-B0A5-84548BBCD121Q34620992-61E22740-ED70-4BE7-B13D-E4D302844054Q34920100-3A441633-903C-4137-B4CC-E94BF5041177Q34988107-A7498C66-240C-4F25-A388-C7C2114C9CE0Q35432757-CC3495A7-6CFA-49BE-A5D1-16428B83529FQ36030203-A2EB7F6D-0453-495B-9778-BB055485D94BQ36671100-482D1924-718C-4A42-A54D-C03EDC1CDCFCQ36693904-B6489711-7F01-489D-84B1-82E083B0A3B8Q36953767-FFC5C0FC-7302-4540-A1F8-EEE564D824EEQ37122213-F1F8DE93-22F9-47AD-A411-DEFEB4CCD91AQ37125113-4EFC7FE3-A6FA-4FA4-A844-018B668E2C98Q37259589-56679F82-3AAC-4FE0-BA53-E8F3B0330C01Q44063968-DD017136-1924-4A9A-A4F0-A72E7BCD0542Q45006115-A6A521CD-ACF8-4C84-A67B-939697F7EB2AQ45028934-0CE9FFAB-1D66-4D1B-8E8C-66C1C3394546Q45179922-8F953C10-A9C1-45F5-BA24-D63028E0DCB5Q45332631-60110208-FCFD-4D12-8D29-6214309CE8B2Q45332939-554DEE1E-FD5C-44DF-92BF-96BEE4B18140Q45332981-BFD13B11-84CF-4267-A608-072096FCA2AAQ45333030-1C375C5F-D58D-4872-9EE9-B4DDB5A17758Q46870294-DDAF849F-5DCA-4C40-9619-97944C079843Q48371548-B9C03731-9B8E-4EEE-B81B-5566C750046A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sander J Robins
@ast
Sander J Robins
@en
Sander J Robins
@es
Sander J Robins
@nl
Sander J Robins
@sl
type
label
Sander J Robins
@ast
Sander J Robins
@en
Sander J Robins
@es
Sander J Robins
@nl
Sander J Robins
@sl
prefLabel
Sander J Robins
@ast
Sander J Robins
@en
Sander J Robins
@es
Sander J Robins
@nl
Sander J Robins
@sl
P106
P21
P31
P496
0000-0002-3735-8415
P569
2000-01-01T00:00:00Z